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Abstract
The rapid rise of particle therapy across the world necessitates evidence to justify its ever-increasing utilization. This
narrative review summarizes the current status of these technologies on treatment of both meningiomas and
gliomas, the most common benign and malignant primary brain tumors, respectively. Proton beam therapy (PBT)
for meningiomas displays high rates of long-term local control, low rates of symptomatic deterioration, along with
the potential for safe dose-escalation in select (but not necessarily routine) cases. PBT is also associated with low
adverse events and maintenance of functional outcomes, which have implications for quality of life and cost-
effectiveness measures going forward. Data on carbon ion radiation therapy (CIRT) are limited; existing series
describe virtually no high-grade toxicities and high local control. Regarding the few available data on low-grade
gliomas, PBT provides opportunities to dose-escalate while affording no increase of severe toxicities, along with
maintaining appropriate quality of life. Although dose-escalation for low-grade disease has been less frequently
performed than for glioblastoma, PBT and CIRT continue to be utilized for the latter, and also have potential for
safer re-irradiation of high-grade gliomas. For both neoplasms, the impact of superior dosimetric profiles with
endpoints such as neurocognitive decline and neurologic funcionality, are also discussed to the extent of requiring
more data to support the utility of particle therapy. Caveats to these data are also described, such as the largely
retrospective nature of the available studies, patient selection, and heterogeneity in patient population as well as
treatment (including mixed photon/particle treatment). Nevertheless, multiple prospective trials (which may partially
attenuate those concerns) are also discussed. In light of the low quantity and quality of available data, major
questions remain regarding economic concerns as well.
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Background
Gliomas are the most frequent primary brain malignan-
cies, and are a diverse constellation of disease ranging
from relatively indolent (World Health Organization
(WHO) Grade 1 pilocytic astrocytoma) to the almost
universally fatal glioblastoma (WHO grade IV). These
also encompass the equally diverse low-grade gliomas
(LGGs, WHO grade II) and anaplastic gliomas (WHO
grade III). Although the prognosis of gliomas varies
based on grade and molecular signature [1], among
other factors, a common element of delivering radiation
therapy (RT) to these neoplasms is the necessity to spare
surrounding organs-at-risk (OARs) from RT dose. To
this extent, the emerging modality of particle therapy,
chiefly comprised of proton beam therapy (PBT) and
carbon ion RT (CIRT), are appealing. The signature
Bragg peak of both beams result in reduced dose distal
to the target of interest, together with a relatively narrow
lateral penumbra, thus sparing adjacent OARs to a
greater degree as compared with photon RT [2].
Meningiomas account for 15–20% of all primary
brain tumors in adults, and are the most common
benign primary neoplasm of the brain [3]. Tumor
classification is highly meaningful, as early RT may be
withheld in low-grade disease, whereas higher-grade
meningiomas (atypical and malignant disease) may
benefit from immediate RT [4]. The high survival
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associated with meningiomas leads to an increased
emphasis on sparing adjacent OARs, in efforts to
maintain neuronal functionality and quality of life
(QOL) in a population that may experience substan-
tial detriment if this is not achieved.
The use of PBT and CIRT is rapidly rising across the
world, and the implementation of this technology has
outpaced the completion of prospective trials that
support its utility. The goal of this review is to highlight
the existing data of PBT and CIRT in meningioma and
adult glioma, as well as postulate future applications and
implications for prospective studies going forward.
Meningioma
PBT for meningioma displays superior dosimetric
profiles as compared to photon-based RT. A planning
study of 10 patients utilizing conventionally-fractionated
RT showed decreased doses to bilateral hippocampi,
cochleae, and whole brain, among many other structures
[5]. Although most cases in the photon group were
intensity-modulated RT (IMRT), there were a couple
patients receiving 3D conformal RT (3DCRT). Neverthe-
less, the study also estimated that the risk of secondary
radiation-induced malignancies could be halved with the
use of PBT.
Clinically, PBT has been utilized to treat meningiomas
since the early 1980s, albeit with non-modern technol-
ogy, imaging, and planning tools. Nevertheless, these
reports have accrued long-term follow-up, demonstrat-
ing expectedly high 5-year recurrence-free and overall
survival (OS) figures of 100% and 93%, respectively [6].
Photon data illustrate local control (LC) rates of 91% at
10 years for benign meningiomas and 81% at 5 years and
53% at 10 years for high-grade disease [3]. A more
contemporary report of PBT for meningioma is largely
associated with critical anatomical areas such as the
skull base [7]. These utilized either single-fraction PBT
radiosurgery (n = 18) or hypofractionated (3-fraction, n
= 5) PBT, and demonstrated 100% LC at median
31 months follow-up in patients treated with PBT radio-
surgery. The LC was 88% in the five patients undergoing
hypofractionated therapy, likely a consequence of the
larger volume of disease treated with fractionation.
Long-term data presented by the Centre de Protonthér-
apie d’Orsay support these results [8]. The investigators
utilized combined photon (2/3 of the total dose) and
proton (1/3 of the total dose) therapy, while displaying the
ability of PBT-mediated dose escalation with a median
dose of 61 Gy relative biological effectiveness (RBE) and
observed a 4-year LC rate of 88%. This is encouraging in
light of the inclusion of atypical and anaplastic histologies.
Importantly, the group published a secondary analysis
displaying that PBT affords low adverse events and main-
tenance of functional outcomes following PBT, which has
high implications for QOL [9]. This group’s work was
updated (n = 24) with more novel techniques as well as
utilization of a more balanced ratio of photons to protons
(mean doses 30.96 and 34.05 Gy(RBE), respectively),
displaying several findings. The most important was the
association of total dose with survival, adding further
significance to the notion of dose-escalation [10]. This
finding is in line with a recent publication from Indiana
University. Despite including patients treated in the
adjuvant and nonoperative setting, the authors determined
that doses of over 60 Gy(RBE) were associated with a
5-year LC of 88%, as compared to just 50% with doses
≤60 Gy(RBE) (p = 0.038) [11]. However, that association
was not evaluated on multivariable analysis; it thus could
have been likely that larger tumors (which are more likely
to recur) received lower doses on account of their size.
Nevertheless, the concept of safe dose-escalation must be
further explored; if proven, it would give particle therapy a
major advantage insofar as permitting safer dose–escal-
ation [12].
Other institutions’ publications have also added to the
encouraging safety and efficacy profiles of PBT for
meningiomas. The Harvard experience from 1996 to
2007 (n = 50) evaluated a single fraction of 13 Gy (RBE),
with just under two-thirds of cases being primary/non-
operative [13]. The 3-year LC was estimated at 94%, with
low rates of RT-associated morbidity; symptomatic
worsening occurred in less than 10% of patients. Next,
an updated report from the Paul Scherrer Institute of 32
patients, mostly treated in the postoperative setting, and
a median dose of 56 Gy(RBE), described long-term out-
comes with a mean follow-up of 62 months [14]. The
treatment was tolerated well, with 5-year LC of 85%,
partially attributed to the higher proportion of postoper-
ative cases and grade I disease, among other salient
factors. Lastly, a large (n = 72) experience of cavernous
sinus meningiomas from Loma Linda University demon-
strated excellent 5-year LC rates of 96% for benign
histology and 50% for atypical histology [15]. Although
most patients were grade I, a token observation was that
larger volumes of disease were still satisfactorily
controlled. Therein, 5-year LC was 100% in patients with
disease ≤20 cm3 versus 95% with tumors over 20 cm3.
Importantly, RT-induced optic toxicities were restricted
to just three patients, all of whom had direct optic nerve
involvement and hence received full dose.
Studies of carbon ion irradiation for meningiomas are
limited to single-institution retrospective reports lump-
ing these cases with other histologies and/or co-
administration of photon-based RT [16, 17]. However,
existing data of atypical/anaplastic meningiomas after
mixed photon-carbon ion treatment (median 50.4 Gy
and 18 Gy(RBE), respectively) with long-term follow-up
(median 77 months) show high rates of primary local
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control (86% at 5 years) with virtually no high-grade
adverse events [12]. Irradiation with photons followed by
a carbon ion boost in the recurrent setting also displays
a 67% rate of local control at 1 year, with no high-grade
toxicities [18]. This question is currently addressed in
the MARCIE trial at the Heidelberg Ion-Beam Therapy
Center (HIT) where subtotally resected high-grade men-
ingioma receive a carbon ion boost with 16 Gy(RBE) in
3 Gy(RBE) fractions combined with an IMRT base plan
of 48-52Gy [19].
There are several analyses and reflections in light of
the overall few existing data for meningioma. Although
PBT has displayed encouraging tumor control rates with
low risk of adverse events, it is important to
contextualize these data. There are multiple discrepan-
cies between the studies discussed herein, including
proportion of patients undergoing surgery prior to RT,
numbers with atypical or malignant disease, and the
large range of irradiated tumor volumes. However,
because RT for meningioma is commonly restricted to
patients who are unsuitable for surgery or incomplete
surgical resection, it is somewhat necessary to lump
heterogeneous patients into a series. It is, nevertheless,
of paramount importance to critically recognize whether
particle therapy actually improves on outcomes of pho-
ton RT for high-risk meningiomas. To this extent, an
additional limitation of these retrospective studies is
clearly related to patient eligibility and selection, which
limits applicability to other cohorts and overall
generalization. Additionally, although it is agreed that
particle therapy offers safer ability to dose-escalate the
tumor while maintaining low doses to OARs, the role of
dose-escalation must be better defined going forward.
This is especially true given the utility of, and recent
increase in, intensity-modulated proton therapy (IMPT),
which can be even more conformal than forward-
planned PBT [20, 21] or single beam optimized proton
plans. Lastly, it remains unresolved whether OAR spar-
ing from the biophysical advantages of PBT translate
into improved clinical outcomes. It is also imperative to
provide long-term functional and QOL data for this neo-
plasm, which may directly impact the perception of
particle therapy by patients and payers.
Glioma
Because PBT affords lower integral brain doses, its dosi-
metric improvements as compared to IMRT may be not-
able in an otherwise largely healthy population of
patients with low-grade gliomas that are expected to
achieve long-term cure with RT-based therapy [22]. For
both LGGs and high-grade gliomas (HGGs), dosimetric
results have predictably shown a dose reduction to
nearby OARs, particularly those farther away from the
target [23–25]. These areas include the hippocampi,
subventricular zones, hearing and visual apparatus, and
pituitary gland. It has also been postulated, similar to
the aforementioned analogous data in meningiomas, that
PBT roughly halves the risk of developing RT-induced
neoplasms as compared with photon-based therapies,
owing to the decreased dose to the whole brain [24],
even though this is of comparatively less importance in
HGGs. Late effects were also studied by Karunamuni et
al., who found a temporal lobe-pronounced dose-
dependent cortical thinning of 0.0033 mm per Gy [26],
which could relate to the higher likelihood of dementia
observed after long-term follow up after radiotherapy
[27, 28]. Hence, dose reductions to potentially every one
of the aforementioned areas have important implications
for the maintenance of QOL and cost-effectiveness
following curative-intent RT, but data are lacking to
support this notion.
Owing to the relative rarity of LGG, the overall volume
of data is comparatively less extensive. However, a
distinct advantage of the available data is the prospective
nature of multiple investigations (discussed subsequen-
tly).The largest study to date, an unpublished retrospect-
ive analysis of 58 patients from the Proton Collaborative
Group registry, illustrated no grade ≥ 3 toxicities when
treated with up to 54 Gy(RBE) (this work did not ascer-
tain clinical outcomes) [29]. The initial Harvard phase I/
II experience (n = 20: n = 7 LGG, n = 13 HGG) demon-
strated several notable findings [30]. First, the ability to
dose-escalate was again apparent, as exemplified by the
cumulative prescribed doses to LGGs and anaplastic
gliomas of 68.2 and 79.7 Gy(RBE), respectively. With
five-year follow-up, despite the fact that just nine
patients received PCV chemotherapy, 5-year OS was a
remarkable 71% (although it is acknowledged that
salvage treatments may impact this figure). Despite
the similarities with contemporary data, treatment
incurred more adverse events than those afforded by
lower doses [22].
A prospective QOL study of 20 patients with LGG
was notable for assessing a diverse array of QOL
measures at many subsequent time points [31]. With a
median follow-up of 5.1 years, there were no declines in
several neurocognitive QOL parameters, along with
statistical improvements in QOL scores for fatigue and
visuospatial parameters. This study had notable limita-
tions, including a relatively heterogeneous cohort com-
prised of both primary (n = 8) and recurrent (n = 12)
LGGs, as well as patients with prior symptomatology lead-
ing to PBT initiation (thus, a potentially altered baseline).
Patients that progressed were also removed from the
study, and QOL for those patients was not included. The
group expanded upon these results by illustrating the
impact of tumor location on improvement in neuro-
psychological testing at long-term follow-up [32].
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Initial evaluation of PBT for glioblastoma was chiefly
in the context of safe dose-escalation. In a phase II study
of 23 patients receiving 90 Gy(RBE) (57.6 Gy(RBE) of
which was delivered with PBT), the median OS was
highly encouraging at 20 months [30]. However, patterns
of failure analysis demonstrated that most recurrences
remained in-field. Thirty percent of patients experienced
radiation necrosis with such high doses.
Dose-escalation for glioblastoma, by means of a hyper-
fractionated concomitant boost technique, was echoed
by both retrospective and prospective reports from the
University of Tsukuba [33, 34]. Concomitantly with de-
livery of 50.4 Gy in 28 fractions with photons,
23.4 Gy(RBE) to a coned-down volume was administered
for the first half of treatment; in the second half, the
same boost dose was given to the entire initial volume.
Thus, the cumulative dose was 96.6 Gy(RBE) in 56 total
fractions. Of 20 patients, there were two cases of nonhe-
matologic grades ≥3 toxicity (leukoencephalopathy and
radiation necrosis), and median OS was 22 months.
Even though the first dose-escalation studies with par-
ticles showed promising results [34–36], there are cur-
rently no high-level data that substantiate the benefit of
dose escalation in this setting [37]. This question will in
part be addressed by the prospective CLEOPATRA trial
at the Heidelberg Ion-Beam Therapy Center (HIT). After
receiving a photon base plan of 50.0 Gy, patients are
randomized to a proton boost (up to 10.0 Gy(RBE) in 5
fractions) versus carbon ions (escalating doses up to
18.0 Gy(RBE) in 6 fractions) [38]. Retrospective data of
this approach using 50.0Gy base plans followed by a
10Gy(RBE) proton boost plan on a reduced target
volume revealed at least equivalent acute and chronic
toxicity rates compared to standard photon plans
(60.0Gy in 2Gy fractions), achieving similar progression
and survival rates [39]. These results are appealing since
smaller target volumes might be associated with im-
proved QOL, neurocognitive- and neuronal function.
Next, because both LGGs and HGGs may recur, a
retrospective investigation evaluated re-irradiation of
26 diverse cerebral cases, 8 of which were re-treated
with PBT (n = 5 glioblastoma, n = 1 anaplastic glioma,
n = 1 ependymoma, n = 1 meningioma) [40]. The me-
dian dose of initial photon RT was 55 Gy, and the
median interval to re-treatment was 16 months in all
patients. The median re-irradiation dose was relatively
low (33 Gy(RBE)), which is important to understand
in the context of no observed grade ≥ 2 toxicities and
two cases of uncomplicated radiation necrosis.
Median OS in the PBT re-treated patients was
19.4 months, which the authors reported as favorable
compared to existing photon literature.
Two phase I/II trials from Chiba University will be
described pertaining to CIRT. First, an investigation
of 48 (n = 16 anaplastic, n = 32 glioblastoma) gliomas
consisted of treatment with 50 Gy of conventionally-
fractionated photon RT with an 8-fraction CIRT boost
(dose ranging from 16.8 to 24.8 Gy(RBE)) with con-
current nimustine chemotherapy. The authors
observed no grade ≥ 3 toxicities, with median OS of
35 months in grade III disease and 17 months in
glioblastoma. Notably, the median progression-free
survival (PFS) and OS in patients treated with the
highest boost doses was 14 and 26 months, respect-
ively [41]. Next, the same working group described a
more uniform population of 14 diffuse grade II astro-
cytoma cases treated with CIRT (46.2–50.4 Gy(RBE)
or 55.2 Gy(RBE)) [36]. Concomitant chemotherapy
was not routinely utilized, but was performed for
select salvage cases. Of the five patients treated to
55.2 Gy(RBE), median PFS and OS were 91 months
and not reached, respectively; corresponding figures
for the remaining 9 patients were 18 and 28 months.
Although these numbers are clearly encouraging, the
causes of the major differences in survival between
the lower-dose and dose-escalated cohorts is unclear.
Although four patients developed grade 3 acute
events, no patient experienced grade ≥ 3 late effects.
As summarized, despite the relatively few data of par-
ticle therapy for glioma, there are also several reflections.
Both LGGs and HGGs are extremely heterogeneous
populations with differing prognoses. As such, although
clinical outcomes were emphasized herein, there is much
more to the complete story than survival, which can be
influenced by molecular signatures of the tumor, salvage
therapies, and other factors. Toxicity reductions are
arguably just as important, but still suffer from the
dependency on patient selection, regardless of whether
the study is retrospective or prospective [39]. Next, al-
though many studies described in this section pertain to
dose-escalation, without clear clinical benefit other than
inherently faulty comparisons with seminal prospective
trials [42, 43], this should still be considered experimen-
tal with particle therapy until randomized data prove a
benefit. Only then toxicity reductions from particle ther-
apy may be of true clinical benefit. Lastly, despite just
one study, the role of particle therapy in re-irradiation
cannot be understated, as potentially serious complica-
tions may occur to a greater degree using escalated
doses (even with particle therapy). However, there
are other confounding factors that prevent the
generalizability of this statement, such as target margins
in the re-treatment setting, availability of high-quality
image-guidance, and potential administration of concur-
rent therapies (e.g. bevacizumab). The ongoing CIN-
DERELLA trial at the University Hospital Heidelberg
and Heidelberg Ion-Beam Therapy Center (HIT) is the
first study to prospectively evaluate carbon ion re-
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irradiation (escalating doses up to 48.0 Gy(RBE) in 16
fractions) for recurrent gliomas, and will compare this
to fractionated stereotactic photon RT (36 Gy in 18
fractions) [44].
Concluding remarks
The striking rise of particle therapy across the world
necessitates evidence to justify its ever-increasing
utilization. Herein, we summarize the current status of
these technologies on treatment of both meningiomas
and gliomas. Overall, with the notable caveat that the
overall quality and quantity of data are low, particle
therapy offers significant safety and efficacy with which
to treat both neoplasms in either a standard, or less
commonly, a dose-escalated setting. Further work must
verify and build upon the lessons learned from these
data and critically assess whether particle therapy is
indeed a necessity in various clinical settings. These data
also have implications on the cost-effectiveness of
particle therapy [45, 46]. Although a complete discussion
is beyond the scope of this article, there may be substan-
tial cost savings associated with a decrease in doses to
several OARs in the many survivors of neoplasms
discussed herein (e.g. meningioma and LGG). However,
a link between dosimetry and clinical toxicity reduction
remains to be proven. For instance, preservation of
memory and quality of life from decreased hippocampal
doses during whole brain RT (a focus of the Radiation
Therapy Oncology Group 0933 trial) [47] are both asso-
ciated with economic cost reductions. Similarly, it may
be extrapolated that particle irradiation for various
clinical settings, tumor locations, and baseline function-
ality may have differential likelihoods of having cost-
effective RT delivery. However, further data are needed
in order to corroborate this notion.
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